Rising Multidrug Resistance and Government Initiatives to Propel Growth in the Antimicrobial Susceptibility Testing Market

Antimicrobial Susceptibility Testing Market is expected to reach $7.21 billion by 2031, at a CAGR of 6.7% during the forecast period

The global burden of infectious diseases continues to rise, fueling the demand for safe and effective diagnostic solutions. Infections entering the bloodstream pose significant health risks, leading to severe conditions like disseminated intravascular coagulation, shock, multiple organ failure, or even death. Common bloodstream infections include sepsis, dengue fever, Acquired Immunodeficiency Syndrome (AIDS), and Hepatitis A, B, and C. Among these, sepsis is particularly prevalent and often leads to organ dysfunction.  

Download Complete Sample PDF Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5062 

According to WHO data from August 2020, there were 48.9 million cases of sepsis worldwide in 2017, resulting in approximately 11 million deaths. Blood culture remains the gold standard for diagnosing septicemia, and antibiotics are critical for treating such life-threatening infections. As a result, there is a growing demand for antimicrobial susceptibility testing to determine the appropriate antimicrobial treatments. 

Hepatitis B is another common infection, with those affected at risk of developing serious liver complications. WHO estimates, updated in July 2020, place the global prevalence of chronic Hepatitis B at 257 million cases by the end of 2015. Early screening for common bacterial infections is essential for timely diagnosis and appropriate treatment management, further increasing the demand for antimicrobial susceptibility testing. 

In addition to the prevalence of infectious diseases, antimicrobial resistance (AMR) has emerged as one of the top 10 global public health threats, according to WHO. Misuse and overuse of antibiotics are major contributors to AMR, which results in nearly 700,000 deaths annually. By 2050, drug-resistant diseases could cause 10 million deaths per year and force up to 24 million people into extreme poverty by 2030. To monitor the spread of AMR, in 2019, a new AMR indicator was included in the Sustainable Development Goals monitoring framework. This tracks bloodstream infections due to two drug-resistant pathogens—E. coli, resistant to third-generation cephalosporins (3GC), and methicillin-resistant Staphylococcus aureus (MRSA). Data from 2019 show that antibiotic resistance averaged 12.11% for methicillin-resistant S. aureus and 36.0% for E. coli resistant to third-generation cephalosporins. The increasing prevalence of AMR is therefore a major driver of demand for antimicrobial susceptibility testing. 

Check complete table of contents with list of table and figures: https://www.meticulousresearch.com/product/antimicrobial-susceptibility-testing-market-5062 

Due to the rising risk of antimicrobial resistance, research and development for new antimicrobials has significantly slowed, leaving the clinical pipeline for new antimicrobials increasingly dry. In 2019, WHO identified 32 antibiotics in clinical development that target priority pathogens, but only six were considered innovative. Additionally, a lack of access to quality antimicrobials remains a critical issue, with shortages impacting healthcare systems in both developed and developing countries. These challenges further underscore the growing demand for antimicrobial susceptibility testing to address current and pipeline antimicrobial agents. 

The emergence of AMR has diminished the effectiveness of antibiotics in treating common infections, leading to treatment failures, prolonged illnesses, increased healthcare costs, and a higher risk of death. The growing number of multidrug-resistant pathogens is driving the need for antimicrobial susceptibility testing. 

Governments worldwide are actively working to raise awareness about the treatment of infections caused by resistant pathogens. Initiatives focused on antimicrobial susceptibility testing are being launched to improve public health. Governments are also partnering with international organizations to develop effective products to combat antimicrobial resistance. For example, in October 2020, the U.S. introduced the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), 2020–2025, aiming to reduce antibiotic resistance through infection prevention, control measures, and optimized antibiotic usage. Similarly, in 2019, the U.K. government published a 20-year vision and a 5-year action plan to combat AMR, with goals to reduce drug-resistant infections by 10% and antibiotic use by 15% by 2025. These initiatives are aimed at educating stakeholders and encouraging investment in research and development to address AMR. In Switzerland, a four-year campaign was launched in 2018 to promote appropriate antibiotic use and raise awareness of AMR. 

Such government-led efforts to combat multidrug resistance are expected to increase the demand for antimicrobial susceptibility testing products, driving the global market. According to Meticulous Research®, the global antimicrobial susceptibility testing market is projected to grow at a CAGR of 6.4%, reaching $5.99 billion by 2028. 

Buy Now: https://www.meticulousresearch.com/Checkout/47104827 

 Contact Us:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research